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Abstract 
A water soluble chloro bridged binuclear copper(II) complex (3) and mononuclear complex (4) 
have been synthesized from chloro substituted 2-oxo-1,2-dihydroquinolin-3-yl-methylene-2 
hydroxybenzohydrazide 1 and 2 and CuCl2·2H2O. The structures of the complexes have been 
determined by single crystal X-ray diffraction. The binding interactions of the ligands and 
complexes with CT-DNA and protein have been evaluated by absorption and emission 
spectroscopic method. CT-DNA and ethidium bromide (EB) competitive studies revealed that 
the compounds could interact with CT-DNA through intercalation binding mode. Interactions of 
the compounds with BSA were also studied by UV−visible, fluorescence and synchronous 
fluorescence spectroscopic methods which showed that the compounds had a strong binding 
affinity with BSA through static quenching process. The cytotoxic effect of the compounds 
examined on cancer cell lines, such as A549 (lung cancer) and MCF7 (breast cancer) cell lines 
showed that all four compounds exhibited substantial cytotoxic activity.  
Keywords: Schiff base ligands, binuclear copper(II) complex, mononuclear copper(II) complex, 
DNA, protein binding and cytotoxic activity. 
Introduction 
In order to assess the potentials of transition metal complexes for applications in bioinorganic 
chemistry, an extensive amount of work has been carried out recently. In all the biological 
systems known so far, the metal ions have been found to be coordinated to various types of 
ligands instead of existing as free ions, and such complexes have shown properties like 
antibacterial, antifungal, anticancer and antitubercular etc.,[1-10] It is very important to investigate 
  
the interaction of such complexes with bio-molecules such as DNA and protein to determine 
their ability to function as drugs. In addition, they have to be subjected to in-vivo and in-vitro 
biological studies if one wishes to design an active drug.  Recently intensive research been 
focused on using metal complexes as drugs against various diseases. Among the metal 
complexes, copper complexes have been shown to exhibit significant biological activities.[11-18] 
Since copper complexes possess biologically accessible redox potentials, high nucleobase 
affinities and displaying high DNA and protein efficiency, copper complexes are a class of the 
most frequently studied and documented as metallonucleases.[19-23] Based on this, active searches 
are on in the synthesis of chloro bridged copper complexes as they show prominent anticancer 
activity.[24] In the design of such complexes, Schiff base ligands are often used to build 
multinuclear metal complexes since they show versatile and functionalities [25] besides exhibiting 
interesting structural, magnetic, biological and catalytic properties.[26] The new complexes have 
been investigated for their binding with DNA and protein to determine the applications in 
biotechnology and medicine. Though a few types of interactions of metal complexes with DNA 
are available, intercalation is one of the most important DNA binding modes, which is related to 
the antitumor activity of the complex.[27] Moreover, studies on interaction of DNA and protein 
with metal complexes will provide information of the structural features that determine the 
therapeutic effectiveness of the complex.[28,29] Given the abundance of copper in nature, it is no 
surprise that medicinal inorganic chemistry focuses on the copper complexes for their potential 
applications in cancer biology.[30,31] Though an extensive amount of research has been done in 
this area, only little amount of work seems to have been done the copper complexes with 
hydrazone ligands derived from chloro sustituted 2-oxo-1,2-dihydroquinoline-3-carbaldehyde. 
Hence, we report herein, the synthesis, characterization and biological studies of copper 
complexes obtained from chloro substituted 2-oxo-1,2-dihydroquinolin-3-yl-methylene-2-
hydroxybenzohydrazides with CuCl2·2H2O.  
Experimental section  
Materials and methods 
All the chemicals used are analytical or chemically pure grade and the water used for the 
experiment was double distilled. 6-chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde and 7-
chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde were prepared according to the literature 
procedures.[32] Solvents were purified and dried according to the standard procedures. [33] FT-IR 
  
spectra (4000-400 cm-1) for the compounds were recorded on a Jasco FT-IR spectrophotometera 
and elemental analyses (C, H, N) were performed on Vario EL III Elemental analyzer 
instrument. Melting points were determined with a Lab India instrument. Electronic absorption 
spectra were recorded using Jasco V-630 spectrophotometer and emission spectra were obtained 
using Jasco FP 6600 spectrofluorometer. The 1H NMR spectra were recorded on Bruker AMX 
500 at 500 MHz spectrometer. EPR spectra of the complexes were recorded on a Bruker 
spectrometer operating at the X-band at room temperature. DNA binding, competitive binding 
fluorescence measurements, protein binding[34,35], cytotoxicity experiments[36] were carried out 
according to the reported procedures. 
Synthesis of the ligands  
(7-Chloro-2-oxo-1,2-dihydroquinolin-3-yl-methylene-2-hydroxybenzohydrazide (1): It was 
prepared by literature method[42] using 2-hydroxybenzohydrazide (1.36 g, 10 mmol) dissolved in 
warm methanol (20 cm3) to a methanol solution (30 cm3) containing 7-chloro-2-oxo-1,2-
dihydroquinoline-3-carbaldehyde (1.73 g, 10 mmol). Yield: 89 %. M.p.: 317-319 ºC. Elemental 
Anal. Calc. for C17H12ClN3O3 (%): C, 59.75; H, 3.54; N, 12.30. Found (%): C, 59.64; H, 3.43; N, 
12.21. FT-IR (cm-1) with KBr disk: 3419 (ʋOH), 1595 (ʋC=N), 1652 (ʋC=O), 3235 (ʋNH): UV-Vis 
(DMSO), λmax (nm) [εmax (dm3mol˗1cm˗1)]: 388 (309300) (intra-ligand transition). 1H NMR (500 
MHz, DMSO-d6, δ, ppm): δ 12.15 (s, 1H, N(1), H), 12.05 (s, 1H, N(3), H), 11.87 (s, 1H, (˗OH)), 
8.69 (s, 1H, (HC=N)), 8.51 (s, 1H, (aromatic), H), 7.98–7.86 (m, 2H, (aromatic), H), 7.46 (t, J = 
7.0 Hz, 1H, (aromatic), H), 7.37 (s, 1H, (aromatic), H), 7.28 (d, J = 8.1 Hz, 1H, (aromatic), H), 
6.96–6.99 (m, 2H, (aromatic), H). 
(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl-methylene-2-hydroxybenzohydrazide (2): 2 was 
prepared by using 6-chloro-2-oxo-1,2-dihydroquinoline-3-carbaldehyde and 2-
hydroxybenzohydrazide. Yield: 89 %. M.p.: 318 ºC. Elemental Anal. Calc. for C17H12ClN3O3 
(%): C, 59.75; H, 3.54; N, 12.30. Found (%): C, 59.60; H, 3.39; N, 12.72. FT-IR (cm-1) with KBr 
disk: 3417 (ʋOH), 1594 (ʋC=N), 1655 (ʋC=O), 3234 (ʋNH): UV-Vis (DMSO), λmax (nm) [εmax (dm3 
mol˗1cm˗1)]: 267 (47200), 382 (588400) (intra-ligand transition). 1H NMR (400 MHz, DMSO-d6, 
δ, ppm): δ 12.20 (s, 1H, N(1), H), 12.08 (s, 1H, N(3), H), 11.85 (s, 1H,(˗OH)), 8.70 (s, 1H, 
(HC=N)), 8.50 (s, 1H, (aromatic), H), 8.04 (s, 1H, (aromatic), H), 7.90 (d, J = 7.8 Hz, 1H, 
(aromatic), H), 7.59 (d, J = 8.8 Hz, 1H, (aromatic), H), 7.46 (t, J = 7.6 Hz, 1H, (aromatic), H), 
7.36 (d, J = 8.8 Hz, 1H, (aromatic), H), 6.94–6.99 (m, 2H, (aromatic), H). 
  
Synthesis of the copper(II) complexes  
Complex 3: Ligand 1 (137 mg, 0.5 mmol) in warm N, N-Dimethylformamide (10 cm3) was 
added to a methanolic solution (20 cm3) of CuCl2·2H2O (121 mg, 0.5 mmol). The resulting 
greenish solution was heated under reflux for 2 hours. Upon cooling, a green colored compound 
was obtained, which was filtered and washed with methanol and dried. Dark green crystals 
suitable for single crystal X-ray diffraction studies were obtained by recrystallization from water. 
Yield: 89 %. M.p.: 342 ºC. Elemental Anal. Calc. for C20H18Cl2CuN4O4 (%): C, 46.84; H, 3.54; 
N, 10.92. Found (%): C, 46.64; H, 3.30; N, 12.58. FT-IR (cm-1) with KBr disk: 3417 (ʋOH), 1574 
(ʋC=N), 1629 (ʋC=O). UV-Vis (DMSO), λmax (nm) [εmax (dm3mol˗1cm˗1)]: 270 (516090) (intra-
ligand transition); 365 (539410) (ligand to metal charge transfer transition), 394 (531770) (ligand 
to metal charge transfer transition). EPR (X-band) at room temperature, ‘g’ value: 2.10. 
Complex (4): 4 were prepared by using the same procedure as described for 3 using of 2. The 
suitable dark green crystals were obtained for single crystal X-ray diffraction studies upon 
recrystallization from water/methanol. Yield: 89 %. M.p.: 338 oC. Elemental Anal. Calc. for 
C18H15Cl2CuN3O4 (%): C, 45.82; H, 3.20; N, 8.91. Found (%): C, 45.78; H, 3.16; N, 8.86. FT-IR 
(cm-1) with KBr disk; 3413 (ʋOH), 1578 (ʋC=N), 1641 (ʋC=O). UV-vis (DMSO), λmax (nm) [εmax 
(dm3mol˗1cm˗1)]: 357 (689000) (ligand to metal charge transfer transition), 418 (444100) (metal 
to ligand charge transfer transition). EPR (X-band) at room temperature, ‘g’ value: 2.09. 
Single crystal X-ray diffraction studies 
Single dark green color block-shaped crystals (3 and 4) of were recrystallized from water and 
water/methanol by slow evaporation. A suitable crystal was selected and mounted on a 
MITIGEN holder in perfluoroether oil on a Xcalibur, Sapphire3 diffractometer. The crystals 
were kept at T = 120(2) K during data collection. Using Olex2[37], the structure was solved by 
direct methods in ShelXS and refined in ShelXL[38] using least squares minimization[39]. 
Crystallographic details are provided in Table 1.  
Results and discussion 
Synthesis and characterization 
Though the reaction of 7-chloro-2-oxo-1,2-dihydroquinolin-3-yl-methylene-2 
hydroxybenzohydrazide with CuCl2·2H2O yielded a chloro bridged binuclear copper complex, a 
very similar reaction with 6-chloro-2-oxo-1,2-dihydroquinolin-3-yl-methylene-2 
hydroxybenzohydrazide resulted in a mononuclear complex. It is quite surprising and difficult to 
  
explain how the change in the position of chloride in the ligand can lead to the formation of two 
types of complexes under a similar reaction condition shown in Scheme 1. They have been 
characterized by IR, elemental analysis, UV−visible, fluorescence spectroscopy, EPR and 1H 
NMR. The molecular structures of the complexes have been determined by single crystal X-ray 
studies, which showed that they are square pyramidal geometry. The compounds are air stable in 
the solid phase and highly soluble in water and also soluble in methanol, ethanol, 
dimethylformamide and dimethylsulfoxide. 
Spectroscopy 
The electronic spectrum of ligands showed two resolved bands one at 267 and the other at 382-
388 nm, which are assigned to intra ligand charge transfer transitions. Complex 3 showed three 
peaks in the region between 270 and 365-394 nm. The band at 270 nm is assigned to intra ligand 
transition, while the band in the region 365-394 is assigned to the ligand-to-metal charge transfer 
transition. Complex 4 showed two absorption bands at 357-418 nm assigned to ligand-to-metal 
charge transfer transition and metal-to-ligand charge transfer transition.[40] The FT-IR spectra of 
the 1 and 2 displayed characteristic absorption bands in the regions 3419–3417, 3235–3234, 
1652–1655 and 1595–1594 cm−1 due to (-OH), (˗NH), (C=O) and (C=N) vibrations respectively. 
The bands due to (˗NH) vibrations observed for the free ligands disappeared completely, which 
indicating enolisation with (˗NH and C=O) followed by deprotonation leading to coordination 
through O atom. The phenolic ˗OH stretching frequency did not show any significant change in 
the spectra of complexes compared to the ligands. The azomethine(C=N) stretching frequency 
have been shifted to lower frequency of 1574-1578 cm−1 in the complexes, which indicated that 
the N atom of C=N coordinated to the metal ion. The IR result suggested that the quinoline based 
hydrazone ligands behave as monobasic tridentate (ONO) chelating ligands in the complex 3 and 
4.[41] In the 1H NMR spectra of the ligands showed in Figures S1 & S2. The signal due to –NH 
proton was observed as a singlet at δ 12.15 and 12.20 ppm in the spectra of 1 and 2. The two 
singlets appeared at δ 11.87 and 11.85 ppm for phenolic ˗OH. A sharp singlet’s appeared at δ 
8.69 and 8.70 ppm, which corresponds to azomethine protons of the ligands 1 and 2 respectively. 
The resonance due to aromatic protons of the ligands at δ 12.05 and 6.97 ppm.[42,43] Copper 
complexes are EPR active due to the presence of an unpaired electron. The +2 oxidation state of 
the copper ion in the complexes was confirmed by X-band EPR the measurements at room 
temperature. The copper complexes 3 and 4 showed well resolved isotropic resonance typical of 
  
square pyramidal Cu(II) system showed in Figures S3 & S4. The trend in the g values 2.10 and 
2.09 for complex 3 and complex 4 respectively. From these values, we suggest that the unpaired 






Scheme 1. Synthesis of ligands and their copper(II) complexes. 
 
Crystallography 
Crystal data and structure refinement for 3 and 4 are shown in Table 1. The complex 3 
crystallized with a distorted square pyramidal monoclinic Cu(II) metal centre with P21/c space 
group. Two units of the ligands coordinated to the metal through two oxygen and one nitrogen 
atoms leading to a dimeric complex with two chloride ligands bridging the two copper ions. The 
complex, which stacks through the chlorine atom of the metal ion, resulted in centrosymmetric 
dimer. Each monomeric unit interacts with another copper centre by a symmetric double chloro 
bridge forming a Cu2Cl2 rectangular core. The double chloro bridged(μ-Cl) connecting both 
Cu(II) ions is symmetric because each Cu(II) center is closer to its own chlorine atom [Cu1–Cl2 = 
2.2394(7) Å. The dihedral angle between the mean planes of the five-member chelate ring and 
  
the six-member are O1-Cu1-O2 is 164.03(8) (º). The molecular structure of the complex 3 
showed in Figure 1. Intramolecular hydrogen bonding exists between the hydroxyl OH and the 
diazine N that is not coordinated to the Cu. In addition, intermolecular hydrogen bonding is 
present between N, N-dimethyl formamide and an amide N showed in Table 2 and Figure 2. π-π 
stacking interactions are also present with just the C4-C9 rings creating stacks in the c-axis 
direction, the rest of the molecule are distorted away from each other and not overlapping 
showed in Table 3 and Figure 3. Important bond lengths and bond angles are tabulated in Table 
S1.  
Complex 4 crystallized with a distorted square pyramidal monoclinic Cu(II) metal centre with 
P21=c space group. The complex contains the ligand coordinated as monobasic ONO tridentate 
manner with the chloride and methanol occupying the fourth and fifth coordination sites. There 
are two independent molecules in the asymmetric unit. In one of them, a molecule of methanol is 
coordinated in the Jahn-teller site while there is disorder between a methanol and water in the 
other molecule. The angle between the mean planes of the four-member chelate ring and the six-
member are O1-Cu1-O2 is 169.42(14) and O7-Cu1-O6 is 170.21(14) (º). The molecular structure 
of the complex 4 showed in Figure 4. Important bond lengths and angles for both the complexes 
are summarized in the Table S1. 
 
Figure 1. Molecular structure of complex (3). Thermal ellipsoid plot for 3 with ellipsoids 
depicted at the 50% probability level. N, N-Dimethylformamide solvent molecule in the lattice is 










Figure 3. The π-π interactions of complex 3. 
  
 
Figure 4. Molecular structure of complex (4). 
 
Table 1: Crystal data and structure refinement for complex 3 and 4 
Compound  3 4 
Empirical formula  C20H18Cl2CuN4O4 C18H15Cl2CuN3O4 
Formula weight  512.82  474.47 
Temperature/K  120(2)  120(2)  
Crystal system  monoclinic  monoclinic  
Space group  P21/c P21/c 
a/Å  15.5275(5)  16.1733(7) 
b/Å  18.4180(6)  10.8489(5) 
c/Å  7.0255(3)  21.7111(11) 
α/°  90  90  
β/°  93.946(4)  100.398(5) 
γ/°  90  90  
Volume/Å3 2004.43(13)  3746.9(3) 
Z  4  8 
ρcalcg/cm3 1.699  1.682 
μ/mm-1 1.394  1.483 
F(000)  1044.0  1924 
Crystal size 0.20 × 0.09 × 0.06 0.33 × 0.09 × 0.08 
2θ range for data collection/°  3.436 to 54.998  3.436 to 54.998  
Reflections collected  18765  30288 
  
Rint 0.0483 0.0877 
Data/restraints/parameters  4593/0/283  7359/0/530 
Goodness-of-fit on F2 1.108  1.061 
Final R indexes [I>=2σ (I)]  R1 = 0.0411, wR2 = 0.0848  R1 = 0.0634, wR2 = 0.1622 
Final R indexes [all data]  R1 = 0.0533, wR2 = 0.0949  R1 = 0.1051, wR2 = 0.1622 
Largest diff. peak/hole / e Å-3 0.47/-0.35  2.04/-0.73 
Table 2. Hydrogen Bond information. 
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/deg 
O3 H3 N2 0.84 1.87 2.603(3) 145.9 
N3 H3A O1S 0.88 1.88 2.703(3) 155.4 
 
Table 3. π-π stacking interactions 
 
Ring Ring Centroid-centroid 
distance (Å) 
Shift distance (Å) 
C4-C9 C4-C9i 3.516 1.011 
C4-C9 C4-C9ii 3.516 0.926 
i +x, ½-y. -1/2+z, ii +x, ½-y, ½+z 
 
DNA binding studies 
Electronic absorption titration: Since DNA is an important cellular target for many metallo-
drugs in treating of multiple pathologies including cancer, an investigation into the binding of 
ligands and metal complexes with DNA is an important one.[44,45] This can be easily done by 
observing the changes in the electronic absorption spectra of the compounds as a function added 
DNA concentration and hence we carried out the interaction of our compounds (10 µM) with 
DNA (0-100 µM) and the results obtained are shown in Figure 5. It has been seen that there was 
a significant change in the absorption summary of 1–4 on sequential addition of DNA. From the 
spectra shown in Figure 5, one can notice that the intensity of absorption decreases resulting in 
hypochromism with a small blue shift. This change indicates that there exists an intercalative 
mode of binding due to the strong stacking interaction between an aromatic chromophore and the 
base pairs of DNA.[46] The extent of shift and hypochromism are normally found to correlate 
with the intercalative binding strength. The magnitude of hypochromism is in the order of 3 > 4 
> 1 > 2, which reflects the DNA binding affinities of the compounds. Further, the intrinsic 
binding constant of the compounds with CT-DNA can be determined using the equation[47] 
[DNA]/[εa-εf] = [DNA] / [εa-εf] + 1/Kb[ εa-εf], where [DNA] is the concentration of DNA in base 
  
pairs. Each set of data, when fitted into the above equation, gave a straight line with a slope of 
1/(εa-εf) and an y-intercept of 1/Kb (εa-εf) Figure 6. The magnitudes of intrinsic binding constants 
Kb calculated values are 0.2753 × 10
6 ± 0.3, 0.2575 × 106 ± 0.27, 1.0835 × 106 ± 0.32 and 0.5019 
× 106 ± 0.29 M-1 for the ligands and complexes. Complex 3 showed better DNA binding affinity 
compared to the other compounds. It is also noted that the addition of CT-DNA to the complex 3 led to 
an isobestic point appearing at 291 nm. The appearance of the isosbestic points suggests that a 
chemical equilibrium exists between the DNA and compound. The enhanced binding of 3 may be due 
the presence of the extension of the π system of the intercalated ligand which leads to a greater 









Figure 6. Plot of [DNA] / [εa-εf] versus [DNA]. 
 
EB displacement study 
The nature of exact binding of the compounds with DNA cannot be obtained from electronic 
spectral data since the compounds showed no fluorescence at room temperature in solution or in 
the presence of CT-DNA. To obtain concrete information, one need to measure emission spectra 
and therefore, the extent of quenching of fluorescence of EB bound to CT-DNA has to be used to 
determine the binding of the second molecule to DNA.[48] This competitive method usually gives 
indirect evidence for the mode of DNA binding.[49] Hence, we carried the recording of the 
emission spectra by adding an increasing amount of our compounds to EB bound DNA excited 
at 624 nm. The emission spectra of EB-DNA in the absence and presence of the compounds 1–4 
are shown in Figure 7. A competitive binding of the ligands and copper complexes to CT-DNA 
resulted in the displacement of bound EB, and as a consequence, the emission intensity 
decreased due to intercalative binding to CT-DNA. The relative order of binding was obtained 
from the linear Stern–Volmer equation[50], I0/I = 1 + Kq[Q]. Here, I0 and I are the fluorescence 
intensities in the absence and presence of the compounds, Kq is a linear Stern–Volmer quenching 
constant, and [Q] is the total concentration of a compounds to that of DNA. The value of Kq is 
given by the ratio of the slope to the intercept in a plot of I0/I versus [Q] showed in Figure 8. The 
EB-DNA fluorescence quenching property constant values obtained are 1.12 × 103 ± 0.002, 1.13 
  
× 103 ± 0.002, 3.04 × 103 ± 0.011 and 2.88 × 103± 0.01 M-1, which indicate the extent of 








Figure 8. Stern–Volmer plot of the compounds with CT-DNA. 
 
Protein binding studies 
Fluorescence and absorbance studies: In addition to the studies carried out so far, protein 
binding study is also essential in determining the ability of a compound to be an active drug. 
Information on this can be obtained by interacting the ligands and the corresponding copper 
complexes with serum albumin through fluorescence spectroscopic studies by measuring the 
intrinsic fluorescence of BSA. Figure 9 shows the changes observed in the intensity fluorescence 
emission of BSA on the addition of increasing amount of the test compounds. The fluorescence 
properties of BSA arise from its intrinsic characteristics, mainly due to the presence of 
tryptophan and tyrosine residues.[51] Addition of the test compounds to the solution of BSA 
resulted in considerable decrease in the fluorescence intensity of BSA at 348 nm accompanied by 
a 1,2,1 and 2 nm blue shift for the compounds 1-4. The fluorescence quenching data were 
analyzed with the Stern−Volmer equation and Scatchard equation showed in Figure 10, 11 and 
Table 4. The quenching constant KSV value was obtained from the plot of I0/I versus [Q] in 
Stern−Volmer equation. Due to the fact that the active site in the protein is buried in a 
hydrophobic environment a blue shift has been observed. This result suggested a definite 
interaction of all the four compounds with the BSA protein and the value of ‘n’ indicates the 
  
existence of a single binding site in BSA for the test compounds. The larger values of Kq for the 








Figure 10. Stern–Volmer plot of the compounds with BSA. 
 
 
Figure 11. Scatchard plot of the compounds with BSA. 
 
Table 4. Binding constant (Kbin), quenching constant (KSV), and number of binding sites (n) for 
the interactions of compounds with BSA. 
Compound       Kbin (M
-1)              KKSV (M
-1)               n 
1          6.28 ±0.14× 102         7.4 ± 0.02× 103         0.69 
2          3.30±0.10 × 102        5.65 ±0.02× 103        0.81 
3          1.43± 0.17× 103        8.49 ±0.02× 103        1.01 
4          9.69 ±0.15× 102        6.89 ±0.02× 103        0.99 
  
The mechanism of quenching is usually classified as dynamic and static. Static quenching refers 
to fluorophore-quencher complex formation in the ground state, and the dynamic quenching 
refers to a process in which the fluorophore and quencher come into contact during the transient 
existence of the excited state. The easiest method to determine the type of quenching is UV-Vis 
absorption spectroscopy. The UV-Vis spectra of BSA in the absence and presence of the 
complexes are shown in Figure 12. The addition of the compounds to a fixed concentration of 
BSA led to a gradual decrease in the intensity of BSA absorption at the same wavelength due to 




Figure 12. Absorbance titration of the compounds with BSA 
 
Synchronous fluorescence spectra 
It further necessary to look at the structural changes occurring to bovine serum albumin upon the 
addition of ligands and complexes and to find out that synchronous fluorescence spectral studies  
of bovine serum albumin has to be carried out. It is a known fact that the fluorescence of bovine 
serum albumin is normally due to the presence of tyrosine, tryptophan and phenylalanine 
residues and synchronous fluorescence spectral studies of serum albumin will indicate the 
presence of any above said three residues. The type of chromophore indicate in the interaction 
  
can be inferred from the difference between the excitation wavelength and emission wavelength 
(Δλ = λemi-λexi).[55] A higher Δλ value such as 60 nm is indicative of the characteristics of 
tryptophan residues while a lower Δλ value such as 15 nm is characteristics of tyrosine 
residues.[56,57] We recorded the synchronous fluorescence spectra of bovine serum albumin with 
various concentrations of our compounds at Δλ=15 nm and Δλ=60 nm. It has been observed that 
there was a decrease in the fluorescence intensity of BSA at 304 and 346 nm. This is an 
indication for the fact that the ligands and complexes induce a fluorescence quenching of 









In order to find out the anticancer properties of the compounds, we carried out the cytotoxic 
investigations against the A549 (lung cancer) and MCF7 (breast cancer) cell lines in aqueous 
solution in comparison with the widely used drug doxorubicin and cisplatin under identical 
conditions by using an MTT assay. The results were analyzed by means of cell inhibition 
expressed as IC50 values and they are shown in Table 5 and Figure 14. After treated by the 
compounds, cancer cell lines change in morphology, and the observed morphological changes 
showed in Figure 15. From the results obtained, it has been noted that dicopper(II) complex 3 
possessed the most potent inhibitory effect against the MCF7 cell line, when its IC50 value is 
compared with that of well-known anticancer drugs doxorubicin and cisplatin. The 
morphological changes examined by staining method suggested that the cell death mechanism 
was through apoptosis. Interestingly, the order of the in vitro anticancer activities of the two 
copper(II) complexes against selected cancer cell lines are in accordance with their DNA and 
protein binding abilities, suggesting that the anticancer activities of the two copper(II) complexes 
may have come from the strong hydrophobic interaction of the compounds with both DNA and 
protein binding. The order of cytotoxicity is doxorubicin ˃ cisplatin˃ 3 ˃ 4 ˃ 2 ˃ 1 for A549 cell 
line and doxorubicin ˃ cisplatin ˃ 3 ˃ 4 ˃ 1 ˃ 2 for MCF7 cancer cell lines.[58-60] 
Table 5. The IC50 values of the compounds 
IC50 values (μM) 
Compound     A-549            MCF-7 
1             34± 0.8         33± 1.4 
2            30± 0.9         35± 1.5 
3             26± 1.5         23± 0.7 
4             29± 1.1         26± 1.4 
Doxorubicin 15± 1.2         16± 1.3 





Figure 14. IC50 values of compounds against A549 and MCF7cell lines. 
 
                                   (A549)                                                             (MCF7) 
Figure 15. Morphological changes observed in the A549 and MCF7 (a, b, c, d control) cells at 
24 h incubation by the treatment of compounds (1-4) (e, f, g, h treated cells).  
Morphological changes in AO/EB and DAPI fluorescence study 
In the designing of potential anticancer drugs, it is important to consider the apoptotic pathways. 
Apoptosis induction is an anti-proliferative mechanism by which the cancer cells undergo 
programmed death and is very beneficial if the new compounds trigger the death of cancer cells 
by apoptosis. To obtain a clear information, it is necessary to characterize the cells undergoing 
apoptosis by morphological and biochemical changes including cell shrinkage, chromatin 
  
condensation and DNA fragmentation.[61] In this connection, the ability of apoptotic cells to 
increase the plasma membrane permeability to certain fluorescent dyes, e.g., AO/EB, Hoechst, 
AO/PI, DAPI etc., is made use of and we studied AO/EB and DAPI staining assays.[62] The 
morphological changes observed in the treated cells are classified into four types on the basis of 
the fluorescence emission and morphological features of chromatin condensation in the AO/EB 
stained nuclei. All these morphological changes were observed after treatment of the cancer cells 
with the ligands and complexes and the changes observed are shown in Figure 16. From the 
figure it can be seen that the green colour of the cells has been converted into orange/red colour 
cells showing an early apoptotic cells with membrane blebbing, which is seen at fixed 
concentration of compounds and untreated A549 and MCF7 cancer cells (control) did not show 
any significant adverse effect as compared to the ones treated by compounds. From DAPI 
fluorescence staining studies, the blue bright patches formed indicates the condensed chromatins 
and nuclear fragmentations in the cancer cells. Further, it is to be also noted that the bright blue 
patches observed in compounds are higher when compared that with untreated A549 and MCF7 
cells showed in Figure 17. The observed results do indicate that complexes 3 and 4 induced cell 
death by apoptosis which is in good agreement with the above cytotoxicity results. 
 
 
                                   (A549)                                                             (MCF7) 
  
Figure 16. AO/EB stained A549 and MCF7 (a, b, c, d control) cells at 24 h incubation by the 
treatment of compounds (1-4) (e, f, g, h treated cells). The yellow and red patches indicate early 
apoptotic in the cancer cells. 
 
 
(A549)                                                                     (MCF7) 
Figure 17. DAPI stained A549 and MCF7 (a, b, c, d control) cells at 24 h incubation by the 
treatment of compounds (1-4) (e, f, g, h treated cells). The bright blue patches show condensed 
chromatins and nuclear fragmentations in the cancer cells. 
Conclusion 
In summary, this work highlights the synthesis, characterization and detailed biological studies 
of a water soluble chloro bridged binuclear copper(II) complex (3) and mononuclear complex (4) 
prepared from the reaction of chloro substituted 2-oxo-1,2-dihydroquinolin-3-yl-methylene-2 
hydroxybenzohydrazide and CuCl2·2H2O. The ligand coordinates to copper ion in a tridentate 
(ONO) manner. The single crystal structures of the complex 3 and 4 indicated square pyramidal 
geometry for both the complexes. The binding abilities of the new complexes with CT-DNA and 
BSA have been investigated by using absorption and fluorescence spectroscopic methods. The 
results indicated that the compounds bind to CT-DNA via intercalation mode and the intrinsic 
fluorescence of BSA was quenched by a static quenching mechanism via hydrophobic 
interaction. All the compounds showed significant in vitro cytotoxic activity against A549 (lung 
cancer) and MCF7 (breast cancer) cell lines. The morphological changes examined by staining 
  
method suggested that the mechanism of cell death was through apoptosis. From the results of 
the above biological studies, we observed that complex 3 has the most significant activity, which 
may be due to the greater planar area that the complex 3 has when compared to that of the others. 
The findings do indicate that the complex 3 may have potential practical applications for 
pharmaceutical development in the future. 
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